Login to Your Account

Antibody-Drug Conjugate Development

ImmunoGen Signs $220M TAP Deal with Eli Lilly

By Catherine Shaffer
BioWorld Today Contributing Writer

Wednesday, December 21, 2011

ImmunoGen Inc. licensed its maytansinoid targeted antibody payload (TAP) technology to Eli Lilly and Co., for the development of a limited number of antibody-drug conjugates for cancer. Lilly will pay $20 million up front and up to $200 million in milestone payments. ImmunoGen will also receive compensation for any research and manufacturing services it may provide to Lilly.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription